Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity

• Published in: Cancer immunology research 2021-11, Vol.9 (11), p.1298-1315
• Main Authors: Hu, Hai, Khodadadi-Jamayran, Alireza, Dolgalev, Igor, Cho, Hyunwoo, Badri, Sana, Chiriboga, Luis A, Zeck, Briana, Lopez De Rodas Gregorio, Miguel, Dowling, Catríona M, Labbe, Kristen, Deng, Jiehui, Chen, Ting, Zhang, Hua, Zappile, Paul, Chen, Ze, Ueberheide, Beatrix, Karatza, Angeliki, Han, Han, Ranieri, Michela, Tang, Sittinon, Jour, George, Osman, Iman, Sucker, Antje, Schadendorf, Dirk, Tsirigos, Aristotelis, Schalper, Kurt A, Velcheti, Vamsidhar, Huang, Hsin-Yi, Jin, Yujuan, Ji, Hongbin, Poirier, John T, Li, Fei, Wong, Kwok-Kin
• Format: Article
• Language: English
• Subjects: Animals; Antigens, Neoplasm - metabolism; Cell Culture Techniques; Cell Line; Cell Proliferation; Histone-Lysine N-Methyltransferase - metabolism; Humans; Mice; Mice, Nude; Neoplasms - genetics; Repressor Proteins - metabolism
• ISSN: 2326-6066; 2326-6074; 2326-6074
• DOI: 10.1158/2326-6066.CIR-21-0543

Substantial progress has been made in understanding how tumors escape immune surveillance. However, few measures to counteract tumor immune evasion have been developed. Suppression of tumor antigen expression is a common adaptive mechanism that cancers use to evade detection and destruction by the immune system. Epigenetic modifications play a critical role in various aspects of immune invasion, including the regulation of tumor antigen expression. To identify epigenetic regulators of tumor antigen expression, we established a transplantable syngeneic tumor model of immune escape with silenced antigen expression and used this system as a platform for a CRISPR-Cas9 suppressor screen for genes encoding epigenetic modifiers. We found that disruption of the genes encoding either of the chromatin modifiers activating transcription factor 7-interacting protein (Atf7ip) or its interacting partner SET domain bifurcated histone lysine methyltransferase 1 (Setdb1) in tumor cells restored tumor antigen expression. This resulted in augmented tumor immunogenicity concomitant with elevated endogenous retroviral (ERV) antigens and mRNA intron retention. ERV disinhibition was associated with a robust type I interferon response and increased T-cell infiltration, leading to rejection of cells lacking intact or . or expression inversely correlated with antigen processing and presentation pathways, interferon signaling, and T-cell infiltration and cytotoxicity in human cancers. Our results provide a rationale for targeting Atf7ip or Setdb1 in cancer immunotherapy.